Keros Therapeutics Announces Board and Executive Changes
Ticker: KROS · Form: 8-K · Filed: Jul 15, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Jul 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
Related Tickers: KROS
TL;DR
Keros T. (KROS) board shakeup and exec comp changes filed.
AI Summary
Keros Therapeutics, Inc. announced on July 9, 2025, changes related to its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and adjustments to compensatory arrangements for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or future performance expectations.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may impact future performance or strategic direction.
Key Numbers
- 001-39264 — SEC File Number (Identifies Keros Therapeutics' filings with the SEC.)
- 81-1173868 — EIN (Employer Identification Number for Keros Therapeutics.)
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- July 9, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-39264 (filing_id) — SEC File Number
- 81-1173868 (ein) — I.R.S. Employer Identification No.
- 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421 (address) — Principal executive offices
- ( 617 ) 314-6297 (phone_number) — Registrant's telephone number
FAQ
What specific roles or individuals are affected by the departure of directors or officers?
The filing indicates the departure of 'Directors or Certain Officers' and 'Appointment of Certain Officers' but does not name specific individuals or their roles in this excerpt.
What are the key changes in compensatory arrangements for officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of report, but the specific details of these arrangements are not provided in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported is dated July 9, 2025.
In which state is Keros Therapeutics, Inc. incorporated?
Keros Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Keros Therapeutics, Inc.?
The principal executive office is located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 15, 2025 regarding Keros Therapeutics, Inc. (KROS).